Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: THVD-201; THVD-202; Tolenix

Latest Information Update: 25 Jan 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TheraVida
  • Developer SK Chemicals; TheraVida
  • Class Alkaloids; Antispasmodics; Benzhydryl compounds; Cresols
  • Mechanism of Action Muscarinic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Overactive bladder

Most Recent Events

  • 01 Sep 2016 SK Chemicals completes a phase-III trial in Overactive bladder in South Korea (PO) (NCT02485067)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Overactive bladder in USA (PO)
  • 10 Aug 2015 No recent reports on development identified - Phase-II for Overactive bladder in Australia, New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top